CHAT LIVE in the only dedicated CHAT ROOM for Corgenix Medical (OTCBB: CONX) shareholders!

M2 PRESSWIRE-25 February 2008-Stockwire.com: CHAT LIVE in the only dedicated CHAT ROOM for Corgenix Medical (OTCBB: CONX) shareholders!(C)1994-2008 M2 COMMUNICATIONS LTD

RDATE:25022008

AUSTIN, TX -- STOCKWIRE.com, one of the largest investment websites on the internet, is proud to announce the official launch of the Corgenix chat room!

Visit the only LIVE CHAT ROOM on the internet dedicated to (OTCBB: CONX) shareholders, by visiting: http://www.stockwire.com

----------------------------------------------------------

DENVER, Feb 25, 2008 - Corgenix to Exhibit AspirinWorks(R) Test at Denver Diabetes Expo.

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will be exhibiting its AspirinWorks(R) Test, booth #312, at the Denver Diabetes Expo, Colorado's largest gathering dedicated to diabetes prevention and management. The Expo is being held in exhibit Hall F at the Colorado Convention Center from 9:00 a.m. - 4:00 p.m. on Saturday, March 1, 2008.

Recent clinical research(1) has noted an increased prevalence of aspirin resistance among diabetic patients (Type II). During treatment with 81 mg aspirin, urinary levels of 11-dehydro thromboxane B2 levels were significantly higher in diabetic patients than non-diabetics. A significant reduction in resistance rates were noted with 325 mg of aspirin treatment as compared to 81mg.

"We know that not all individuals respond the same to the same dose of aspirin, and aspirin resistance is a concern of anyone taking aspirin to prevent heart attack and stroke," said Corgenix' Clinical Affairs Director Gordon Ens. "This is a great opportunity for the diabetic community and related medical professionals to learn more about the issue of aspirin resistance and how it may potentially impact management of type II diabetes."

AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.

The AspirinWorks Test, which was launched in the United States in June 2007 following FDA 510(k) clearance, is now available nationwide through major medical reference laboratories as well as direct to consumers through HealthCheckUSA (www.HealthCheckUSA.com).

Unlike other platelet tests, which require freshly drawn blood that must be evaluated within at least 4 hours, the AspirinWorks test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 ext. 180, or e-mail: info@aspirinworks.com. More information is also available at www.aspirinworks.com.

The Denver Diabetes Expo event features free screenings and exercise demos, guest celebrities, interactive educational sessions, a diabetes bookstore, El Mercadito Latino/Latin Marketplace, and exhibits featuring the latest products and services for diabetes awareness and management.

About Corgenix Medical Corporation: Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network.

----------------------------------------------------------

About Stockwire: Stockwire is one of the largest communities for Micro Cap Investors. We are the only place on the internet to provide LIVE CHAT ROOMS for dedicated stocks.

We have also pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.

The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.

Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.

As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.

While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.

Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml

Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.

From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.

The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.

We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.

While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm.

CONTACT: The Stockwire GroupTel: +1 512 358 8440e-mail: info@stockwire.com

((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data prepared by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).